BreCanSurvPred

BreCanSurvPred assesses the impact of adherence to endocrine therapy (ET) on survival outcomes in estrogen receptor-positive breast cancer using population-based survival analyses.

Key Features:

• Population-Based Dataset: Uses a cohort of 1,268 estrogen receptor-positive breast cancer patients diagnosed in Girona and Tarragona, Northeastern Spain, stratified by HER2 status, stage at diagnosis, and adherence to ET.
• Cox Regression Analysis: Employs Cox regression to identify prognostic factors influencing all-cause mortality, highlighting cancer stage and ET adherence.
• Relative Survival Estimation: Calculates relative survival (RS) to estimate the crude probability of death due to breast cancer (PBC).
• Hazard Ratio Quantification: Quantifies the effect of adherence on mortality risk with reported hazard ratios, including HR 0.57 for adherent versus non-adherent patients.
• Stage-Specific Survival Probabilities: Provides survival probabilities across cancer stages showing higher PBC for non-adherent patients and increasing risk with advancing stage.
• Age-Adjusted Survival Curves: Derives age-adjusted survival curves from the modeling to present survival outcomes adjusted for patient age.
• Adherence Impact Visualization: Demonstrates differences in mortality risk between adherent and non-adherent patients across stages and ages.

Scientific Applications:

• Clinical prognostic communication: Supports oncologists in discussing the survival impact of ET adherence with breast cancer patients using data-driven survival indicators.
• Population-based research: Enables researchers to analyze adherence-related outcomes and stage-specific survival trends in a regional breast cancer cohort.

Methodology:

Analysis uses a population-based cohort stratified by HER2 status, stage, and ET adherence; Cox regression to identify prognostic factors; calculation of relative survival (RS) to estimate PBC; modeling to derive age-adjusted survival curves and hazard ratios.